0000000000482962

AUTHOR

Guiu Boris

0000-0003-1277-3054

showing 13 related works from this author

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOL…

2020

PurposeThe objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to compare it to the RECIST1·1 and morphological criteria defined by changes in homogeneity and borders.MethodsThis study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed. In 230 patients, computed texture analysis was performed on the dominant liver lesion (DLL) at baseline and 2 months after chemotherapy. RECIST1·1 evaluation was performed at 6 months. …

MaleOncologyColorectal cancermedicine.medical_treatmentLeucovorinKaplan-Meier Estimate030218 nuclear medicine & medical imagingMESH: Camptothecin / administration & dosage; Camptothecin / analogs & derivatives; Colorectal Neoplasms / drug therapy; Colorectal Neoplasms / pathology; Computational Biology; Female0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overLiver NeoplasmsGastroenterologyMESH: Radiographic Image Interpretation Computer-Assisted; Response Evaluation Criteria in Solid Tumors; Survival Rate;Tomography X-Ray ComputedMiddle AgedBevacizumabSurvival Rate030220 oncology & carcinogenesisCohortFOLFIRIRadiographic Image Interpretation Computer-AssistedFemaleFluorouracilColorectal NeoplasmsClinical decision makingmedicine.drugAdultmedicine.medical_specialtyBevacizumab[SDV.CAN]Life Sciences [q-bio]/CancerMESH: Fluorouracil / administration & dosage; Humans; Kaplan-Meier Estimate; Leucovorin / administration & dosage; Liver Neoplasms / diagnostic imagingComputerised image analysis03 medical and health sciencesColorectal metastasesMESH: Adult; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols / administration & dosage; Bevacizumab / administration & dosage; Camptothecin / administration & dosagePredictive Value of TestsInternal medicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansChemotherapyResponse Evaluation Criteria in Solid TumorsMESH: Liver Neoplasms / secondary; Male; Middle Aged; Predictive Value of Tests; Prospective StudiesAgedChemotherapybusiness.industryComputational Biology[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseColorectal cancerLog-rank testIrinotecanCamptothecinTomography X-Ray ComputedbusinessGut
researchProduct

Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.

2012

International audience; PURPOSE: To compare pure molecular diffusion, D, perfusion-related diffusion, D*, and perfusion fraction, f, determined from diffusion-weighted (DW) magnetic resonance (MR) imaging on the basis of the intravoxel incoherent motion (IVIM) theory in patients with type 2 diabetes with and without liver steatosis. MATERIALS AND METHODS: This prospective study was approved by the appropriate ethics committee, and written informed consent was obtained from all patients. Between December 2009 and September 2011, 108 patients with type 2 diabetes (51 men, 57 women; mean age, 50 years) underwent 3.0-T single-voxel point-resolved proton MR spectroscopy of the liver (segment VII…

MaleCirrhosisMagnetic Resonance SpectroscopyMESH : Fatty Liver[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingMESH : AgedMESH : Prospective Studies030218 nuclear medicine & medical imagingMESH: Linear Models0302 clinical medicineNuclear magnetic resonanceMESH: Aged 80 and overMESH : Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseMESH : Linear ModelsNonalcoholic fatty liver diseaseMESH : FemaleProspective StudiesMESH: Fatty LiverIntravoxel incoherent motion[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overMESH: AgedMESH: Statistics NonparametricMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingFatty liverMiddle AgedMESH : AdultMESH : Diffusion Magnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisPotential confounderFemaleRadiologyMESH: Diabetes Mellitus Type 2Adultmedicine.medical_specialtyMESH : MaleMESH: Diffusion Magnetic Resonance ImagingStatistics Nonparametric03 medical and health sciencesmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingMESH : Middle AgedMESH : Aged 80 and overMESH : Statistics NonparametricAgedMESH: Humansbusiness.industryMESH: Magnetic Resonance SpectroscopyMESH : HumansMESH: Biological MarkersMESH: Adultmedicine.diseaseMr imagingMESH: MaleMESH: Prospective StudiesFatty LiverMESH : Biological MarkersDiffusion Magnetic Resonance ImagingDiabetes Mellitus Type 2Linear ModelsMESH : Magnetic Resonance SpectroscopySteatosisbusinessMESH: FemaleBiomarkersDiffusion MRI
researchProduct

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

2011

Abstract Background There is no consensus about the most effective method for transarterial chemoembolisation of hepatocellular carcinoma. Aim The aim of this phase II trial was to compare the efficacy and toxicity of lipiodol transarterial chemoembolisation with amiodarone in association with pirarubicin or doxorubicin versus lipiodol transarterial chemoembolisation with anthracycline alone in a control group. Methods Patients with unresectable hepatocellular carcinoma and Child-Pugh A/B7 were considered eligible for the trial. transarterial chemoembolisation was repeated every 6 weeks for a maximum of 4 sessions. Results Thirteen patients were randomised in the amiodarone group, and 14 we…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAnthracyclinePirarubicinAmiodaroneKaplan-Meier EstimateAmiodaroneGastroenterologyDisease-Free Survivallaw.inventionExcipientsEthiodized OilRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansChemoembolization TherapeuticAgedHepatologybusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseSurgeryClinical trialTreatment OutcomeDoxorubicinHepatocellular carcinomaLipiodolFemalebusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Impact économique de la chimioembolisation avec microsphères chargées dans le traitement du carcinome hépatocellulaire

2011

Resume La chimioembolisation est le traitement de premiere ligne pour les patients atteints d’un carcinome hepatocellulaire (CHC) non resecable, non metastatique. Les microspheres chargees d’anticancereux recemment commercialisees ont pour objectif d’augmenter l’efficacite de la chimioembolisation en permettant un relargage controle et prolonge de l’anticancereux au plus proche de la tumeur. Notre etude monocentrique compare selon deux methodes de valorisation, les couts medicaux hospitaliers directs d’une premiere cure de chimioembolisation conventionnelle et d’une premiere cure de chimioembolisation avec microspheres chez 30 patients atteints de CHC. Le cout moyen valorise par la comptabi…

Cancer ResearchOncologyRadiology Nuclear Medicine and imagingHematologyGeneral MedicineBulletin du Cancer
researchProduct

Bone marrow fat quantification of osteoporotic vertebral compression fractures: comparison of multi-voxel proton MR spectroscopy and chemical-shift g…

2011

Background Only a few studies have used in/opposed phase method for a quantitative evaluation of fat fraction in the spine. Purpose To compare multivoxel proton MR spectroscopy and chemical-shift gradient-echo MR imaging for bone marrow fat quantification in vertebral compression fractures (VCF). Material and Methods Vertebral marrow fat quantification in fifteen patients was measured at 3.0-T. Multi-voxel proton spectroscopy (MRS) and in/opposed-phase MR imaging using a fat map build with a triple-echo gradient-echo sequence was used. All the patients had benign vertebral collapse. Bone marrow fat content was evaluated by both techniques in compressed (acute or chronic) and in non-compress…

MaleIn vivo magnetic resonance spectroscopyMagnetic Resonance Spectroscopy[SDV]Life Sciences [q-bio]Fat quantificationcomputer.software_genreMESH: Magnetic Resonance Imaging030218 nuclear medicine & medical imagingMESH: Aged 80 and over0302 clinical medicineBone MarrowVoxelFractures CompressionMESH: Fractures CompressionAged 80 and overMESH: AgedMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingRadiological and Ultrasound TechnologyGeneral MedicineMiddle AgedCompression (physics)LipidsMagnetic Resonance Imagingmedicine.anatomical_structureAcute DiseaseSpinal FracturesMESH: Acute DiseaseFemaleMESH: Bone MarrowMESH: OsteoporosisAdultMESH: Spinal Fractures03 medical and health sciences[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansRadiology Nuclear Medicine and imagingAgedMESH: HumansMESH: Magnetic Resonance Spectroscopybusiness.industryMESH: Chronic DiseaseVertebral compression fractureMESH: Adultmedicine.diseaseMESH: LipidsMr imagingMESH: MaleProton mr spectroscopyChronic DiseaseOsteoporosisBone marrowbusinessNuclear medicineMESH: Femalecomputer030217 neurology & neurosurgeryActa Radiologica
researchProduct

Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice.

2010

The constitutive androstane receptor (CAR) is a nuclear receptor expressed in the liver and involved in xenobiotic metabolism. The aim of this study was to assess whether pharmacological CAR activation could affect neutral sterol and bile acid elimination under conditions of cholesterol overload.Wild type, Car-/-, ApoE-/-, and low-density lipoprotein receptor (Ldlr)-/- mice fed a western-type diet were treated with the CAR agonist TCPOBOP.CAR activation was associated with a decrease in faecal cholesterol output related to the repression of the Abcg5/g8 cholesterol transporters. In contrast, TCPOBOP treatment induced a marked increase (up to three fold, p0.01) in the elimination of faecal b…

medicine.medical_specialtymedicine.drug_classPyridinesLipoproteinsBiological Transport ActiveGene ExpressionReceptors Cytoplasmic and NuclearHyperlipidemiasBiologyCholesterol 7 alpha-hydroxylaseBile Acids and Saltschemistry.chemical_compoundFecesMiceApolipoproteins EInternal medicineConstitutive androstane receptormedicineAnimalsHomeostasisATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorConstitutive Androstane ReceptorMice KnockoutHepatologyBile acidCholesterolReverse cholesterol transportATP Binding Cassette Transporter Subfamily G Member 8Cholesterol HDLAtherosclerosisSterolMice Inbred C57BLEndocrinologyCholesterolchemistryLiverReceptors LDLLDL receptorlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersJournal of hepatology
researchProduct

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic age…

2011

Abstract Purpose. A better identification of patients who are more likely to benefit from vascular endothelial growth factor–targeted therapy is warranted in metastatic renal cell carcinoma (mRCC). As adipose tissue releases angiogenic factors, we determined whether parameters such as visceral fat area (VFA) were associated with outcome in these patients. Experimental Design. In 113 patients with mRCC who received antiangiogenic agents (bevacizumab, sunitinib, or sorafenib) (n = 64) or cytokines (n = 49) as first-line treatment, we used computed tomography to measure VFA and subcutaneous fat area (SFA). We evaluated associations linking body mass index (BMI), SFA, and VFA to time to progres…

SorafenibOncologyMaleCancer Researchmedicine.medical_specialtygenetic structuresIntra-Abdominal FatBevacizumabPopulationAngiogenesis InhibitorsIntra-Abdominal FatCohort StudiesGenitourinary Cancer: Renal Bladder and TesticularRenal cell carcinomaInternal medicinemedicineHumansNeoplasm MetastasiseducationSurvival rateCarcinoma Renal CellAgedRetrospective Studieseducation.field_of_studyNeovascularization PathologicSunitinibbusiness.industrymedicine.diseasePrognosisKidney NeoplasmsSurvival RateEndocrinologyTreatment OutcomeOncologyDisease ProgressionFemalebusinessBody mass indexmedicine.drugThe oncologist
researchProduct

Liver methylene fraction by dual- and triple-echo gradient-echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness…

2011

Purpose To assess the systematic errors in liver methylene fraction (LMF) resulting from fat–fat interference effects with dual- and triple-echo gradient-recalled-echo Dual/Triple GRE) sequences and to test the robustness of these sequences after iron overloading. Materials and Methods Forty type-2 diabetic patients underwent LMF measurement by 3.0T 1H magnetic resonance spectroscopy (corrected for T1 and T2 decays) as the reference standard and liver fat fraction (%Fat) measurement by four Dual/Triple GRE sequences with 20° and 60° flip angle (α), corrected for T1 recovery. The same four sequences were repeated in eight patients after ferumoxide injection. Corrections for systematic errors…

MaleMagnetic Resonance SpectroscopyMESH : Fatty LiverMESH: Echo-Planar Imaging[SDV]Life Sciences [q-bio]Carbon Compounds InorganicMESH : Statistics as TopicStatistics as TopicMESH : AgedContrast MediaMESH : Carbon Compounds InorganicMESH : Tissue Distribution030218 nuclear medicine & medical imagingCorrelationchemistry.chemical_compound0302 clinical medicineMESH : DextransNon-alcoholic Fatty Liver DiseaseMESH : FemaleTissue DistributionMESH: DextransMethyleneMagnetite NanoparticlesMESH: Fatty LiverMESH: AgedMESH: Middle Agedmedicine.diagnostic_testEcho-Planar ImagingDextransNuclear magnetic resonance spectroscopyMESH : AdultMiddle AgedMESH: Reproducibility of ResultsAdipose TissueLiverFemale030211 gastroenterology & hepatologyMESH : Sensitivity and SpecificityProtonsMESH: Adipose TissueAdultIron OverloadMESH : MaleMESH: Magnetite NanoparticlesMESH : Adipose TissueSensitivity and SpecificityMESH: Iron Overload03 medical and health sciencesFlip angleRobustness (computer science)MESH: Contrast MediaLinear regressionmedicineMESH : ProtonsHumansMESH : Middle AgedRadiology Nuclear Medicine and imagingMESH: Tissue DistributionMESH: Statistics as TopicAgedMESH : Contrast MediaMESH : Iron OverloadMESH: HumansMESH : Echo-Planar Imaging[ SDV ] Life Sciences [q-bio]MESH: Magnetic Resonance Spectroscopybusiness.industryMESH : Reproducibility of ResultsMESH : HumansMESH: Biological MarkersMESH: Carbon Compounds InorganicMESH : LiverMESH : Magnetite NanoparticlesReproducibility of ResultsMESH: AdultMagnetic resonance imagingMESH: MaleMESH: Sensitivity and SpecificityProton mr spectroscopyMESH : Biological MarkersFatty LiverchemistryMESH : Magnetic Resonance SpectroscopyMESH: ProtonsNuclear medicinebusinessMESH: FemaleBiomarkersMESH: LiverJournal of Magnetic Resonance Imaging
researchProduct

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

2013

Abstract Background Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysisLogistic regressionGastroenterologyCohort StudiesHepatitis B ChronicLiver Cirrhosis AlcoholicRisk FactorsInternal medicinemedicineHumansIn patientAspartate AminotransferasesChemoembolization TherapeuticAdverse effectAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyAcute Kidney InjuryHepatitis C ChronicLiver Failure AcuteMiddle Agedmedicine.diseaseUniversity hospitalTumor BurdenSurgeryLogistic ModelsTreatment OutcomeDoxorubicinHepatic EncephalopathyHepatocellular carcinomaMultivariate AnalysisToxicityFemaleChemical and Drug Induced Liver InjuryIdarubicinbusinessDigestive and Liver Disease
researchProduct

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubici…

2016

Objectives The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD). Setting This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. Patients had to complete the EORTC QLQ-C30 HRQoL questionnaire at baseline and at days 15, 30 and 60 after TACE. Participants Patients aged ≥18 years with HCC unsuitable for curative treatments were evaluated for the study (N=21). Primary and secondary outcome measurements The …

MaleOncologyHealth-related Quality of LifePhases of clinical research[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of life1506FatigueAntibiotics AntineoplasticLiver NeoplasmsGeneral MedicineMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisHepatocellular carcinomaToxicityFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology030211 gastroenterology & hepatology1717medicine.drugmedicine.medical_specialtyCarcinoma HepatocellularMaximum Tolerated Dose1722Pain[SDV.CAN]Life Sciences [q-bio]/CancerPhase 1Disease-Free Survival03 medical and health sciencesInternal medicineCarcinomamedicineHumansIdarubicinChemoembolization TherapeuticAgedHealth-related Quality of ifeOncology clinical trialHealth related quality of lifebusiness.industryResearchlongitudinal analysis[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologyphase Imedicine.diseaseSurgeryTime to deteriorationMaximum tolerated doseQuality of LifeIdarubicinbusinessBMJ Open
researchProduct

Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.

2020

International audience; Hepatocellular carcinoma is the fourth leading cause of cancer death. For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization. To date, the overall survival at three years remains low, and there is currently no consensus about the best anticancer agent and optimal treatment regimen. We report the case of a hepatocellular carcinoma patient with a vascular contraindication to embolization who achieved a complete response after four intra-arterial infusions of idarubicin emulsified with lipiodol. The patient maintained his response over a three-year period without any hepatocellular carcinoma treatment, dem…

MaleHepatocellular carcinoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterologyEthiodized Oil0302 clinical medicineMESH: Infusions Intra-ArterialMESH: Liver NeoplasmsPharmacology (medical)EmbolizationMESH: Carcinoma HepatocellularComplete responseMESH: Treatment OutcomeMESH: AgedStandard treatmentLiver Neoplasms[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodol030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyIntra-arterial therapyCarcinoma HepatocellularAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesMESH: Ethiodized OilInternal medicinemedicineHumansInfusions Intra-ArterialIdarubicinContraindicationAgedMESH: Humansbusiness.industryMESH: Idarubicinmedicine.diseasedigestive system diseasesMESH: MaleRegimenMESH: Antineoplastic AgentsbusinessIdarubicin
researchProduct

Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

2010

International audience; Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease, resulting in increased local drug concentrations. Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy. The patient was treated with a combination of gemcitabine and oxaliplatin using HAI. The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI. The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed…

OncologyMale[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/SurgeryOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCase ReportDeoxycytidineMetastasischemistry.chemical_compound0302 clinical medicineHepatic ArteryAntineoplastic Combined Chemotherapy Protocols[ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery0303 health sciencesLiver NeoplasmsGastroenterologyvirus diseasesGeneral MedicineMiddle AgedMagnetic Resonance Imaging3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsCatheter AblationAdenocarcinomaDeoxycytidinemedicine.drugmedicine.medical_specialtyanimal structures[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryAdenocarcinoma03 medical and health sciencesHepatic arterial infusionInternal medicinemedicineHumansInfusions Intra-Arterial030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseGemcitabineGemcitabineOxaliplatinchemistrybusinessTomography X-Ray Computed
researchProduct

Transcatheter embolization of a renal artery pseudoaneurysm after open partial nephrectomy.

2011

Twelve days after an open partial nephrectomy, a 31-year-old man was re-admitted urgently for acute lumbar pain. An emergent helical computed tomography scan with intravenous contrast revealed a 3-cm renal artery pseudoaneurysm at the site of the partial nephrectomy, which was responsible for a large perirenal hematoma. Transarterial hyperselective embolization successfully occluded the pseudoaneurysm with less than 1 mL of N-butyl-2-cyanoacrylate, an embolizing agent less costly than coils. The kidney parenchyma was fully preserved.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentContrast MediaNephrectomyPseudoaneurysmLumbarRenal Arterymedicine.arteryMedicineHumanscardiovascular diseasesEmbolizationRenal arteryKidneybusiness.industryAngiographyGeneral MedicineEnbucrilatemedicine.diseaseEmbolization TherapeuticNephrectomySurgeryClear cell renal cell carcinomamedicine.anatomical_structureTreatment Outcomecardiovascular systemPerirenal hematomaSurgeryTissue AdhesivesRadiologybusinessTomography X-Ray ComputedAneurysm FalseAmerican journal of surgery
researchProduct